Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Hosted on MSN
Jim Cramer on Recursion: “It is so low that it comes in under the category of speculative”
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer discussed, along with the tech battleground. Answering a caller’s query about the stock during the lightning round, Cramer ...
Micah Castelo is a web editor for EdTech: Focus on K-12. Her experience includes education and community news coverage for the Syracuse Post-Standard and international news reporting for the Pulitzer ...
Kaitlin Sullivan is a health and science journalist based in Colorado. She's been part of multiple award-winning investigations into health topics including the international medical device industry ...
This guide was reviewed by a Business News Daily editor to ensure it provides comprehensive and accurate information to aid your buying decision. Modern businesses run on data. Companies regularly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback